Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zansecimab, an antibody targeting ANGPT2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Melrilimab, an antibody targeting IL1RL1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Izuralimab, an antibody targeting ICOS × PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Alomfilimab, an antibody targeting ICOS.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Golocdacimab, an antibody targeting OLR1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Galegenimab, an antibody targeting HTRA1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tobemstomig, an antibody targeting PD-1 × LAG-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tarperprumig, an antibody targeting ALB × CFP.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Perenostobart, an antibody targeting ENTPD1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Reflocibart, an antibody targeting VEGFB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Varisacumab, an antibody targeting VEGF-A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rulonilimab, an antibody targeting PD-1.